| KN25022 |
| KEY NOTE CONTRACEPTION : October 2002 |
|
|
CLICK
 TO BUY |
This report covers: contraception, contraceptives, oral contraceptives, the pill, iud, condom, the coil, natural family planning, AIDS,
Companies covered include: Janssen-Cilag, Organon Laboratories, Pfizer Group, Pharmacia, Schering Health Care, Ssl International, Wyeth Europa Ansell, Condomi, Lamberts (Dalston),
EXECUTIVE SUMMARY
In 2001, the UK market for contraception was valued at £139.4m, an increase of 2.3 percent on the total of £136.2m in 2000. Incorporating both consumer products and prescription drugs, the contraceptives market is an unusual one. While market growth overall remains stable, sector-specific shifts reflect broader changes in opinions, attitudes and consumer behaviour.
The market is also segmented according to the way in which the contraceptive works: barrier products, hormone-based products, intra-uterine products and other methods. Barrier products, which include both condoms and the cap/diaphragm, and which dominate the consumer product sector, account for the largest share of the market in terms of value. Hormone-based products, and in particular oral contraceptives, continue to account for the bulk of the remainder of the market. It is also within this sector that new product development is most prolific, with breakthrough formulations and revolutionary methods of use currently bringing new life into the market.
Trends in the use of contraceptives are inextricably linked not only to demographics, but also to wider social shifts — such as the rising age at which women are choosing to have children and changing patterns of sexual behaviour. Such trends not only affect overall market growth, but also instigate sector-specific change as the user profile alters. Health concerns remain an important factor in the market's performance. Adverse media coverage about health risks drastically affects all sectors and, for this reason, the industry continues to research safer options.
The hormone-based contraceptives sector, in particular, continues to be held back by legislation preventing the advertising of prescription products direct to consumers. An extremely significant development since 2000 was the licensing of the morning-after pill to be sold over the counter, thus reclassifying it from prescription drug to consumer product. This represented an important turning point for the contraceptives market as it could point to further changes in the way contraceptives are classified. Furthermore, the increasing use of emergency contraception indicates both an area of potential growth and a need for increased awareness among the sexually active population about different forms of contraception. The principal trend in the contraception market over the next few years will be the development of new products largely in response to increasing demand for both convenience and safety. Hormone-based contraceptives will continue to dominate but, within the sector, new formulations and methods of application will gradually begin to encroach on market share. Major trends in the condom market include the growth of pleasure-orientated products and the wider availability of condoms in general.
TABLE OF CONTENTS
| Executive Summary 1 |
| 1. Market Definition 7 |
| report coverage 7 |
| MARKET SECTORS 7 |
| Barrier Products 7 |
| Hormone-Based Products 7 |
| Oral Contraceptives 8 |
| Depot Contraceptives 8 |
| Intra-Uterine Products 8 |
| Other Methods 8 |
| MARKET TRENDS 9 |
| MARKET POSITION 9 |
| Key Trade Associations 9 |
| Association of British Pharmaceutical Industry 9 |
| British Pregnancy Advisory Service 10 |
| Brook Advisory Centres 10 |
| Department of Health 10 |
| FPA (formerly Family Planning Association) 10 |
| Health Development Agency 11 |
| Marie Stopes International 11 |
| National Pharmaceutical Association 11 |
| Royal Pharmaceutical Society of Great Britain 11 |
| 2. Market Size 12 |
| the TOTAL MARKET 12 |
| Table 1: The UK Contraception Market by Sector by Value (£m), 1997-2001 12 |
| BY MARKET SECTOR 13 |
| Barrier Products 13 |
| Table 2: The Barrier Products Sector by Subsector by Value (£m and percent), 1997-2001 13 |
| Hormone-Based Products 14 |
| Table 3: The Hormone-Based Products Sector by Subsector by Value (£m and percent), 1997-2001 14 |
| Intra-Uterine Products 15 |
| Table 4: The Intra-Uterine Products Sector by Subsector by Value (£m and percent), 1997-2001 16 |
| Other Methods 16 |
| 3. Industry Background 17 |
| Recent History 17 |
| Number of Companies 17 |
| Employment 17 |
| Distribution 18 |
| HOW ROBUST IS THE MARKET? 18 |
| Table 5: Total UK Female Population by Age Group (000 and percent), 1996, 1998 and 2000 19 |
| LEGISLATION 20 |
| 4. Competitor Analysis 21 |
| THE MARKETPLACE 21 |
| MARKET LEADERS 21 |
| Janssen-Cilag 21 |
| Company Structure 21 |
| Current and Future Developments 22 |
| Financial Results 22 |
| Organon Laboratories Ltd 22 |
| Company Structure 22 |
| Current and Future Developments 22 |
| Financial Results 23 |
| Pfizer Group Ltd 23 |
| Company Structure 23 |
| Current and Future Developments 24 |
| Financial Results 24 |
| Schering Health Care 24 |
| Company Structure 24 |
| Current and Future Developments 24 |
| Financial Results 25 |
| SSL International PLC 26 |
| Company Structure 26 |
| Current and Future Developments 26 |
| Financial Results 27 |
| Wyeth Europa Ltd 27 |
| Company Structure 27 |
| Current and Future Developments 27 |
| Financial Results 27 |
| OTHER COMPANIES 27 |
| Ansell Ltd 27 |
| Condomi 28 |
| Lamberts (Dalston) Ltd 28 |
| ADVERTISING AND PROMOTION 28 |
| Table 6: Main Media Advertising Expenditure on Contraceptive Products by Type and Brand (£000), 2001-2002 29 |
| Exhibitions and Trade Shows 30 |
| 5. Strengths, Weaknesses, Opportunities and Threats 31 |
| the total MARKET 31 |
| Strengths 31 |
| Weaknesses 31 |
| Opportunities 31 |
| Threats 32 |
| Barrier products 32 |
| Strengths 32 |
| Weaknesses 32 |
| Opportunities 32 |
| Threats 33 |
| Hormone-based products 33 |
| Strengths 33 |
| Weaknesses 33 |
| Opportunities 33 |
| Threats 34 |
| Intra-uterine products 34 |
| Strengths 34 |
| Weaknesses 34 |
| Opportunities 34 |
| Threats 35 |
| other Methods 35 |
| Strengths 35 |
| Weaknesses 35 |
| Opportunities 35 |
| Threats 35 |
| 6. Buying Behaviour 36 |
| introduction 36 |
| Table 7: Chosen Method of Contraception Among Women Aged Between 16 and 49 ( percent), 1995, 1997 and 1999 36 |
| Contraceptive prescription 37 |
| Prescription by GPs 37 |
| Table 8: General Practitioner Prescriptions by Type (000 and percent), 1997-2001 37 |
| Prescription by Family Planning Clinics 39 |
| Table 9: First Contacts of Women Attending Family Planning Clinics by Type of Contraception ( percent), 1997-2001 40 |
| CONTRACEPTIVE USAGE 41 |
| Changing Trends in Contraceptive Usage 41 |
| Table 10: Family Planning Clinic Prescriptions Written by Type ( percent), 1975, 1980, 1985, 1990, 1995 and 2001 41 |
| Post-Coital Contraception 43 |
| Table 11: Post-Coital Contraceptive Prescriptions Written at Family Planning Clinics in England by Type (000 prescriptions), 1997-2001 43 |
| Table 12: Post-Coital Contraceptive Prescriptions Written at Family Planning Clinics by Type and Age Group (000 prescriptions and percent), 2000-2001 44 |
| Abortion and Contraception 45 |
| Table 13: Number of Abortions to UK Residents by Gestation Length (number of weeks and 000), 1995, 1997 and 1999 45 |
| The Consumer Market for Condoms 45 |
| Table 14: Usage of Condoms by Sex, Age Group and Social Grade ( percent of adults), 2002 46 |
| Table 15: Usage of Condoms by Frequency ( percent of adults), 2002 47 |
| 7. Current Issues 49 |
| MORE OPTIONS FOR POST-COITAL CONTRACEPTION AND ABORTION 49 |
| TARGETING TEENS: GOVERNMENT PLANS TO INCREASE ACCESS TO CONTRACEPTIVE SERVICES 49 |
| IS IT SAFE? HEALTH ISSUES AN ONGOING CONCERN 50 |
| EXPANDING CHOICES: NEW PRODUCTS ON THE MARKET AND IN THE PIPELINE 51 |
| 8. The Global Market 52 |
| US WOMEN CHOOSE PLEASURE OVER FUNCTIONALITY: BUT TEENAGERS 'JUST SAY NO' 52 |
| EUROPE: INTERNET GROWTH DISSOLVES INFORMATION BARRIERS 53 |
| NEED FOR CONTRACEPTIVES IN DEVELOPING COUNTRIES INCREASES — BUT SUPPLY CONTINUES TO FALL SHORT 54 |
| 9. Forecasts 55 |
| INTRODUCTION 55 |
| Forecasts 2002 to 2006 55 |
| Table 16: The Forecast UK Contraception Market by Sector by Value (£m), 2002-2006 56 |
| Future Trends 56 |
| New Product Development 56 |
| Increasing Awareness 57 |
| Strategies and Society 57 |
| Over-The-Counter Emergency Contraception 57 |
| 10. Company Profiles 58 |
| Janssen-Cilag Ltd 59 |
| Organon Laboratories Ltd 61 |
| Pfizer Group Ltd 63 |
| Pharmacia Ltd 65 |
| Schering Health Care Ltd 67 |
| Ssl International Plc 69 |
| Wyeth Europa Ltd 71 |
| 11. Further Sources 73 |
| Associations 73 |
| Publications 73 |
| General Sources 74 |
| Bonnier Information Sources 75 |
| Government Publications 76 |
| Other Sources 77 |
Text © 2002 Key Note
| Can't find what you
need? Try our "Research on Request" market report service and define your own report research! Fixed prices - £150, £450 and £1,250 - and fixed delivery of 4, 5 and 14 days |
| Click here for full details |
Ariadne - working together with our customers
to enhance productivity and increase knowledge
© 2004
www.the-list.co.uk Ariadne
Last updated by Amanda Porteous February 2004
